Published on in Vol 9 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/54665, first published .
Correction: The Patient Experience of Acute Lymphoblastic Leukemia and Its Treatment: Social Media Review

Correction: The Patient Experience of Acute Lymphoblastic Leukemia and Its Treatment: Social Media Review

Correction: The Patient Experience of Acute Lymphoblastic Leukemia and Its Treatment: Social Media Review

Corrigenda and Addenda

1Research Triangle Institute Health Solutions, Manchester, United Kingdom

2Pfizer Inc, New York City, NY, United States

Corresponding Author:

Rebecca Crawford, MA

Research Triangle Institute Health Solutions

The Pavilion, Towers Business Park

Wilmslow Road

Manchester, M20 2LS

United Kingdom

Phone: 44 161 447 6040

Email: rcrawford@rti.org



In “The Patient Experience of Acute Lymphoblastic Leukemia and Its Treatment: Social Media Review” (JMIR Cancer 2023;9:e39852), the authors made two updates.

A plain language summary was included as Multimedia Appendix 2.

The following sentence was added to the Conclusion, referring to the plain language summary:

Information about this study in a plain language format is available in Multimedia Appendix 2.

The correction will appear in the online version of the paper on the JMIR Publications website on December 20, 2023, together with the publication of this correction notice. Because this was made after submission to PubMed, PubMed Central, and other full-text repositories, the corrected article has also been resubmitted to those repositories.

Multimedia Appendix 1

Plain language summary.

PDF File (Adobe PDF File), 263 KB

This is a non–peer-reviewed article. submitted 17.11.23; accepted 21.11.23; published 20.12.23.

Copyright

©Rebecca Crawford, Slaven Sikirica, Ross Morrison, Joseph C Cappelleri, Alexander Russell-Smith, Richa Shah, Helen Chadwick, Lynda Doward. Originally published in JMIR Cancer (https://cancer.jmir.org), 20.12.2023.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cancer, is properly cited. The complete bibliographic information, a link to the original publication on https://cancer.jmir.org/, as well as this copyright and license information must be included.